Lundbeck strikes $250M Abide buyout, bagging Tourette's drug

Lundbeck strikes $250M Abide buyout, bagging Tourette's drug

Submitted by admin on May 6, 2019 - 10:50am
Source: 
Fierce Biotech
News Tags: 
Lundbeck
Abide Therapeutics
M&A
Tourette's syndrome
Headline: 
Lundbeck strikes $250M Abide buyout, bagging Tourette's drug
snippet: 

Lundbeck is set to pay $250 million (€223 million) up front to buy Abide Therapeutics. The deal will give Lundbeck a phase 2a Tourette's syndrome program, a CNS drug discovery platform and a West Coast research hub.

Do Not Allow Advertisers to Use My Personal information